Scottish biotech company, and the market leader in gene therapy control technologies, Synpromics, has been bought by AskBio, the American pioneer in gene therapeutics.  EIS and VCT fund manager Calculus Capital, which first invested in Synpromics in 2015 and invested £5.6m into the company in total, will receive a return on investment that significantly exceeds target returns.